The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Programmed cell death ligand 1 <scp>d</scp>isruption by <scp>clustered regularly interspaced short palindromic repeats</scp>/Cas9‐genome editing promotes antitumor immunity and suppresses ovarian cancer progression2019 · 58 citations
2. 2Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015 · 8,648 citations
3. 3Non-small cell lung cancer: current treatment and future advances2016 · 2,045 citations
4. 4PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer2019 · 108 citations
5. 5KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC2019 · 38 citations